Article

Essilor receives AOA seal for UV absorbers/blockers

Dallas-Essilor of America Inc. announced recently that the American Optometric Association (AOA) awarded its Seal of Acceptance for Ultraviolet Absorbers/ Blockers to Essilor's Varilux Airwear progressive lenses, along with its Ovation, Essilor Natural, and Adaptar progressive lenses made with Airwear material.

Dallas-Essilor of America Inc. announced recently that the American Optometric Association (AOA) awarded its Seal of Acceptance for Ultraviolet Absorbers/ Blockers to Essilor's Varilux Airwear progressive lenses, along with its Ovation, Essilor Natural, and Adaptar progressive lenses made with Airwear material.

The AOA's Seal of Acceptance for Ultraviolet Absorbers/Blockers is one of nine categories in the AOA Seal of Acceptance Program. The AOA's Commission on Ophthalmic Standards evaluates the quality of ophthalmic products, devices, and instruments. It specifies the minimum requirements and test procedures for acceptance of products for the AOA Seal of Acceptance for Ultraviolet Absorbers/Blockers.

"Essilor is thrilled to receive a Seal from the AOA for the second time. Select Airwear progressive lenses join Thin&Lite 1.67, which received the AOA Seal of Acceptance for Ultraviolet Absorbers/Blockers last year," said Carl Bracy, vice president of marketing for Essilor of America. "The Seal helps eye-care professionals assure patients that they are offering the best the industry has to offer."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.